{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=46",
    "query": {
      "condition": "Safety Study",
      "page": 46
    },
    "page_size": 10
  },
  "pagination": {
    "page": 46,
    "page_size": 10,
    "total_count": 33591,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=47&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=45&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T12:32:54.789Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04936178",
      "title": "A Study of NB003 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "NB003 tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ningbo Newbay Technology Development Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2021-08-06",
      "completion_date": "2025-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-11-19T12:32:54.789Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Jacksonville, Florida • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Long Island City",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04936178"
    },
    {
      "nct_id": "NCT04184115",
      "title": "Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Motion Sickness"
      ],
      "interventions": [
        {
          "name": "DPI-386 Nasal Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Repurposed Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 102,
      "start_date": "2019-06-09",
      "completion_date": "2019-06-11",
      "has_results": false,
      "last_update_posted_date": "2019-12-03",
      "last_synced_at": "2026-11-19T12:32:54.789Z",
      "location_count": 1,
      "location_summary": "Long Beach, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04184115"
    },
    {
      "nct_id": "NCT05664243",
      "title": "A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Autologous genetically modified gamma-delta T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Allogeneic genetically modified gamma-delta T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "In8bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2023-09-08",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-19T12:32:54.789Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Louisville, Kentucky + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05664243"
    },
    {
      "nct_id": "NCT00412035",
      "title": "Botox Injection for Lower Extremity Lengthening and Deformity Correction Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unequal Length of Limbs; Congenital",
        "Lower Extremity Deformities, Congenital"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin A injection",
          "type": "DRUG"
        },
        {
          "name": "saline injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shriners Hospitals for Children",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "5 Years to 21 Years"
      },
      "enrollment_count": 125,
      "start_date": "2007-01",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2014-12-23",
      "last_synced_at": "2026-11-19T12:32:54.789Z",
      "location_count": 4,
      "location_summary": "Wilmington, Delaware • Honolulu, Hawaii • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00412035"
    },
    {
      "nct_id": "NCT00610935",
      "title": "Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Peramivir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioCryst Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 82,
      "start_date": "2008-01",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-11-19T12:32:54.789Z",
      "location_count": 96,
      "location_summary": "Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more",
      "locations": [
        {
          "city": "Millbrook",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00610935"
    },
    {
      "nct_id": "NCT06465108",
      "title": "Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypoparathyroidism"
      ],
      "interventions": [
        {
          "name": "MBX 2109",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "MBX Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 64,
      "start_date": "2024-08-08",
      "completion_date": "2025-06-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-11-19T12:32:54.789Z",
      "location_count": 27,
      "location_summary": "Sacramento, California • Jacksonville, Florida • Miami, Florida + 22 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06465108"
    },
    {
      "nct_id": "NCT03489525",
      "title": "MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Dose Escalation, MEDI2228, ADC (antibody drug conjugate)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Expansion, MEDI2228, ADC (antibody drug conjugate)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "101 Years",
        "sex": "ALL",
        "summary": "18 Years to 101 Years"
      },
      "enrollment_count": 107,
      "start_date": "2018-05-08",
      "completion_date": "2022-03-21",
      "has_results": false,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-11-19T12:32:54.789Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03489525"
    },
    {
      "nct_id": "NCT07337525",
      "title": "A First in Human Study of PLT012 in Participants With Solid Tumor Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Tumor",
        "Solid Tumor Cancer"
      ],
      "interventions": [
        {
          "name": "PLT012",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pilatus Biosciences Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2026-02-13",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-11-19T12:32:54.789Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Dallas, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07337525"
    },
    {
      "nct_id": "NCT00168740",
      "title": "Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "1995-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-09-15",
      "last_synced_at": "2026-11-19T12:32:54.789Z",
      "location_count": 29,
      "location_summary": "Little Rock, Arkansas • Duarte, California • La Jolla, California + 25 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00168740"
    },
    {
      "nct_id": "NCT06830863",
      "title": "A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "EGFR Inhibitor-associated Rash"
      ],
      "interventions": [
        {
          "name": "ATR04-484",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Azitra Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2025-08-25",
      "completion_date": "2027-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-19T12:32:54.789Z",
      "location_count": 6,
      "location_summary": "Hot Springs, Arkansas • New Haven, Connecticut • New York, New York + 3 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Gahanna",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06830863"
    }
  ]
}